ONS Publishes Manual on Psychosocial Aspects of Oncology Care

Publication
Article
OncologyONCOLOGY Vol 12 No 2
Volume 12
Issue 2

The Oncology Nursing Society (ONS) announces the publication of Psychosocial Dimensions of Oncology Nursing Care. The module, which will be available in early 1998, addresses the psychosocial aspects that affect the patient with cancer and provides practical interventions.

The Oncology Nursing Society (ONS) announces the publication of Psychosocial Dimensions of Oncology Nursing Care. The module, which will be available in early 1998, addresses the psychosocial aspects that affect the patient with cancer and provides practical interventions.

The module is designed as a broad overview of common psychosocial concerns in cancer care and provides a review of assessment techniques and practical strategies to assist patients, families, and caregivers. The major subject headings include:

  • Coping with cancer;
  • Patient and family issues;
  • Spirituality;
  • Survivorship;
  • Sexuality;
  • Body image;
  • Death, dying, and bereavement;
  • Alterative therapies; and
  • Self-care for nurses.

Within each of these subject headings are detailed and specific strategies and suggestions for dealing with the day-to-day problems faced by patients and their families.

The manual can be purchased for $15 (ONS member) and $18 (nonmember). To order the manual, contact: ONS Customer Service Department, 501 Holiday Drive, Pittsburgh, PA 15220, or call (412) 921-7373.

Recent Videos
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Related Content